RIVERSIDE, Calif., July 1, 2026 /PRNewswire/ — U.S. Customs and Border Protection (CBP), through its sales agents Amentum and CWS Marketing Group, will conduct the second and final public auction of approximately 12,000 tons of seized aluminum profiles on July 23, 2026, in Riverside, California.

This auction represents the final offering of aluminum profiles seized by CBP in 2017. The first auction successfully sold approximately 10,000 tons, with this event offering the remaining inventory of more than 24 million pounds.

The aluminum is located at the Amentum Consolidated Storage Facility (CSF) in Riverside and consists of approximately 161,409 non-functional “pallets” stored outdoors in 623 shipping containers, which are included in the sale. The material is predominantly 6000-series high-grade aluminum alloy, with a small percentage consisting of A356 alloy. Independent laboratory analysis confirmed the aluminum is suitable for recycling and remelting for use in manufacturing across a variety of industries, including aerospace, construction, automotive, and transportation.

The July 23rd auction will feature one bulk lot totaling more than 24 million pounds of aluminum stored in shipping containers. The sale will be conducted live in Riverside, California, with online bidding available through CWS Marketing Group for those who cannot attend in-person. Participation is limited to CBP-approved buyers.

A refundable $100,000 earnest-money deposit is required for auction participation. Inspection appointments are available at the Riverside facility on July 8, July 15, and July 22, 2026. Interested bidders must schedule an appointment in advance. Appointments can be made online at cwsmarketing.com.

The controlled liquidation of federally seized materials supports responsible asset management while returning forfeiture proceeds to federal law enforcement and victim assistance programs. Recycling aluminum also provides significant environmental benefits, using approximately 95 percent less energy than producing primary aluminum.

For additional information, bidder registration, or inspection appointments, visit CWSMarketing.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/us-customs-to-auction-12-000-tons-of-seized-aluminum-in-riverside-california-302816220.html

SOURCE U.S. Customs and Border Protection

Now live on mainnet, Robinhood Chain has adopted Chainlink as its official data and cross-chain oracle to power Robinhood Stock Tokens, including NVDA, GOOG, AAPL, and more.

NEW YORK, July 1, 2026 /PRNewswire/ — Robinhood Chain, Robinhood’s Ethereum-based layer 2 blockchain, has adopted Chainlink as its official data and cross-chain oracle infrastructure powering Robinhood Chain and all Robinhood-issued assets, including Stock Tokens like NVDA, GOOG, AAPL, and more. As part of the strategic integration, Chainlink’s Cross-Chain Interoperability Protocol (CCIP), Data Streams, and Data Feeds are now live on Robinhood Chain mainnet from day one, delivering verifiable data for tokenized RWAs and unlocking secure interoperability across the multi-chain ecosystem. Via Chainlink, millions of users now have unlocked access to onchain products within the Robinhood Chain ecosystem.

As one of the world’s largest financial apps going all-in on blockchain infrastructure, this marks a major milestone for the mainstream consumer adoption of onchain finance. Through Chainlink, Robinhood Chain is now natively connected across chains and able to offer its users highly secure real-world assets at scale — all powered by market-leading infrastructure that secures over 70% of DeFi and has enabled more than $31 trillion in transaction value.

Without institutional-grade oracle infrastructure, tokenized assets cannot scale or maintain the security required by regulated market participants. Operating as an Ethereum layer-2 network built on Arbitrum’s Orbit technology, Robinhood Chain addresses these inefficiencies with Chainlink by establishing an environment built specifically to unlock advanced onchain finance use cases for everyday Robinhood users.

“We’re excited to see Robinhood Chain adopt Chainlink as the official data and cross-chain oracle infrastructure powering Robinhood Chain and unlocking access to the onchain economy for millions of users. This is how the world’s largest financial services apps accelerate the transition to an onchain financial system powered by Chainlink.” — Thodoris Karakostas, Director of Global Partnerships, Chainlink Labs

“Robinhood Crypto is building the foundation for the future of investing by delivering secure access to all of our financial products directly onchain, through Robinhood Chain. We chose Chainlink as the oracle provider for Robinhood Chain because its institutional-grade security and reliability are already trusted by the world’s largest financial institutions to scale onchain ecosystems.” — Gaëtan Thabot, Director of Product, Robinhood Crypto

About Chainlink
Chainlink is the industry-standard oracle platform bringing the capital markets onchain and the market leader powering the majority of DeFi. The Chainlink stack provides the essential data, interoperability, compliance, and privacy standards needed to power advanced blockchain use cases for institutional tokenized assets, lending, payments, stablecoins, and more. Since inventing decentralized oracle networks, Chainlink has enabled tens of trillions in transaction value and now secures the vast majority of DeFi.

Many of the world’s largest financial services institutions have also adopted Chainlink’s standards and infrastructure, including Swift, Euroclear, Mastercard, Fidelity International, UBS, S&P Dow Jones Indices, FTSE Russell, WisdomTree, ANZ, and top protocols such as Aave, Polymarket, Lido, Lighter, and many others. Chainlink leverages a novel fee model where offchain and onchain revenue from enterprise adoption is converted to LINK tokens and stored in a strategic Chainlink Reserve. Learn more at chain.link.

View original content to download multimedia:https://www.prnewswire.com/news-releases/robinhood-chain-launches-and-adopts-chainlink-to-unlock-access-to-the-onchain-economy-for-millions-of-users-302816242.html

SOURCE Chainlink

A major biopharmaceutical company has filed a First-in-Human (FIH) clinical trial application with drug product manufactured using the PAK BioSolutions system. The milestone demonstrates the platform’s performance in GMP clinical manufacturing environments.

Drug product manufactured using the PAK BioSolutions purification system supports clinical trial submission, demonstrating real-world performance in GMP clinical manufacturing.

VIENNA, Va., July 1, 2026 /PRNewswire-PRWeb/ — PAK BioSolutions today announced that a major biopharmaceutical company has successfully filed a First-in-Human (FIH) clinical trial application with drug product manufactured using the PAK BioSolutions system.

The PAK platform was utilized in GMP clinical manufacturing operations, supporting production of drug product used in the clinical filing. The outcome demonstrates the system’s ability to operate within regulated manufacturing environments where consistency, control, and compliance are required.

The successful FIH filing represents a meaningful validation point for the PAK System in clinical-stage manufacturing. Use of the platform in GMP operations aligned with a clinical submission highlights its capability to support drug development programs as they advance toward human trials.

“Supporting a First-in-Human filing is an important step in demonstrating the readiness of the PAK System for GMP clinical manufacturing,” said Joanna Pezzini, CEO at PAK BioSolutions. “This milestone reflects the ability of the platform to meet specifications and deliver reliable performance in a highly regulated environment.”

The use of the PAK System by a major biopharmaceutical company reflects increasing industry interest in continuous manufacturing approaches that can increase productivity and reduce manufacturing costs.

The PAK System is designed to operate multiple steps simultaneously, including:

ChromatographyVirus InactivationFiltrationUFDF

Its continuous manufacturing approach enables over 4X faster production or 4X greater output from an existing facility footprint. New facilities can be built with a 60% footprint reduction and 50% cost reduction.

Organizations preparing for clinical manufacturing are increasingly evaluating platforms based on their ability to reduce costs while maintaining process consistency with scale up. Demonstrated use of the PAK systems in a clinical filing provides an important reference point for those assessments.

For additional information about the PAK System for GMP clinical manufacturing, visit PAKBioSolutions.com.

About PAK BioSolutions

PAK BioSolutions is a bioprocessing technology company advancing continuous manufacturing solutions for biopharmaceutical production. The PAK System enables GMP-grade, scalable, and efficient drug manufacturing across process development, clinical, and commercial applications.

Media Contact

Gregory Isaacs, PAK BioSolutions, 1 (703) 849-4900, gregory.isaacs@pakbiosolutions.com, https://pakbiosolutions.com/

View original content:https://www.prweb.com/releases/major-biopharmaceutical-company-files-first-in-human-trial-supported-by-pak-biosolutions-gmp-purification-system-302816092.html

SOURCE PAK BioSolutions